AusperBio Secures $37 Million Series A Financing to Advance HBV Cure Candidate AHB-137 and Expand Med-Oligo™ Platform

Data from Pharma Intelligence Cloud (www.pharnexcloud.com) showsAusperBio (Hangzhou Haobo Pharmaceutical Co., Ltd. and AusperBio Therapeutics, Inc.) has recently completed a Series A financing round of $37 million (approximately 268 million RMB). This round was led by InnoPinnacle Fund with additional investments from Vivo Capital, HanchorBio Capital, Qiming Venture Partners, and YuanSheng Capital. The proceeds will primarily be used to rapidly advance the Phase II clinical trial of AusperBio's potential cornerstone hepatitis B cure, AHB-137, as well as combination therapy exploration and CMC production among other development efforts. Additionally, the funds will support the expansion of the proprietary Med-Oligo™ technology platform and its product pipeline.

Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, stated: "We are extremely honored to have completed this significant financing in the current market environment. This financing not only signifies recognition of our R&D achievements but also provides crucial momentum for the next chapter of AusperBio. The successful completion of this financing, along with AHB-137 recently receiving approval from the CDE to be designated as a breakthrough therapy, allows us to further accelerate the clinical development of AHB-137."

Dr. Yang Chengyong, Co-founder and CSO of AusperBio, stated: "We are deeply honored to collaborate with many outstanding investment institutions, and we sincerely appreciate their support and trust. AusperBio integrates cutting-edge oligonucleotide technology with highly efficient and precise targeted delivery technology, successfully developing AHB-137 under our self-developed Med-Oligo™ platform. The positive Phase I clinical data for this drug recently attracted significant attention at the European Association for the Study of the Liver (EASL) Annual Meeting, marking our international leadership in the field of HBV clinical cure. This round of financing will further advance the clinical research of AHB-137, benefiting patients worldwide sooner and creating greater value for society."

JoinPharm陌VIP Dry Goods Shop Get the latest dry goods resources